Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome;Efeitos da rosiglitazona sobre a função endotelial em indivíduos não-diabéticos com síndrome metabólica

Arquivos Brasileiros de Cardiologia

Volumn 86, Issue 5, 2006, Pages 366-373

  Bahia, Luciana ^a,b   Aguiar, Luiz Guilherme K ^a   Villela, Nivaldo ^a   Bottino, Daniel ^a   Godoy Matos, Amélio F ^a   Bouskela, Eliete ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NONE   (Brazil)

Author keywords

Endothelium; Metabolic syndrome; Rosiglitazone

Indexed keywords

ACETYLCHOLINE; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; LIPID; NITROPRUSSIDE SODIUM; ROSIGLITAZONE; VASODILATOR AGENT;

ADULT; ARTICLE; BODY MASS; CELL ACTIVATION; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; FOREARM BLOOD FLOW; HUMAN; INSULIN RESISTANCE; LABORATORY TEST; MALE; METABOLIC SYNDROME X; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; MALE; METABOLIC SYNDROME X; RISK FACTORS; THIAZOLIDINEDIONES; VASODILATION; VASODILATOR AGENTS;

EID: 33744980004     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2006000500007     Document Type: Article

References (52)

1. Ross R. Atherosclerosis: an inflammatory disease. N Eng J Med. 1999; 340: 115-26.
2. Libby P, Ridker P, Maseri A. Inflammation and Atherosclerosis. Circulation. 2002; 105: 1135-43.
3. Behrendt D, Ganz P. Endothelial function: from biology to clinical applications. Am J Cardiol. 2002; 21: 40L-48L.
4. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long term follow up in patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101: 948-54.
5. Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol. 1999; 84: 11J-14J.
6. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288: 2709-16.
7. Isomaa B, Almgren P, Forsen B, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24: 683-9.
8. Pinkey JH, Stehouwer CDA, Coppack SW, Yudkin JS Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 1997; 46 (suppl 2): S9-S13.
9. Hsueh WA, Christopher JL, Quiñones MJ. Insulin resistance and the endothelium. Am J Med. 2004; 117: 109-17.
10. Andreas F, D'Agostino R, Howard G, Mykkanen L, Russel T, Haffner S. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000; 102: 42-7.
11. Guido A, Cretti A, Balzano A, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. 2002; 105: 576-82.
12. Vakkilainen J, Makimattila S, Seppala-Lindroos A, et al. Endothelial dysfunction in men with small LDL particles. Circulation. 2000; 102: 716-21.
13. Fagan TC, Deedwania PC. The cardiovascular dysmetabolic syndrome. Am J Med. 1998; 105 (suppl): 77S-82S.
14. Vamecq J, Latruffe N. Medical signicance of peroxisome proliferators-activated receptors. Lancet. 1999; 354: 141-8.
15. Yki-Jarvinen H. Thiazolidinediones. N Eng J Med. 2004; 351: 1106-18.
16. Gurnell M, Savage DB, Krishna V, O'Rahilly S. The metabolic syndrome: peroxisome proliferators-activated receptor and its therapeutic modulation. J Clin Endocrinol Metab. 2003; 88: 2412-21.
17. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004; 89: 2728-35.
18. Maeda N, Takahasi M, Finahasi T, et al. PPAR gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50: 2094-9.
19. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator- activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002; 25: 376-80.
20. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 2004; 27: 484-90.
21. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-421.
22. WHO - Physical Status: The use and interpretation of anthropometry, Report of a WHO Expert Committee. Geneva, 1995 - Technical Report Series 854.
23. Chobanian AV, Bakris Gl, Black HR, et al. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Hypertension. 2003; 42: 1206-52.
24. Sociedade Brasileira de Diabetes. Consenso Brasileiro sobre Diabetes: Diagnóstico e Classificação e Tratamento do Diabetes Mellitus Tipo 2. Rio de Janeiro: Diagraphic, 2003: 16-18.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Teacher DF, Turner RC. Homeostasis model assessment: insulin resistance and b cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985; 28: 412-9.
26. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000; 85: 2402-10.
27. Haffner SM, Miettinen H. Insulin resistance implications for type ii diabetes mellitus and coronary heart disease. Am J Med. 1997; 103: 152-62.
28. Hanley A, Williams K, Stern M, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio Heart Study. Diabetes Care. 2002; 25: 1177-84.
29. Haffner SM, Greenberg AS, Weston WM, Chen H, Willians K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002; 106: 679-84.
30. Sidhu JS, Cowan D, Kaski JC. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol. 2004; 15; 94: 151-6.
31. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2004; 93: 362-5.
32. Caballero AE, Saouaf R, Linn SC, et al. The effects of troglitazone on the endothelial function in early and late diabetes: a placebo controlled randomized clinical trial. Metabolism. 2003; 52: 173-80.
33. Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004; 27: 1349-57.
34. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-Kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000; 101: 1539-45.
35. Goya K, Sumitani S, Xu X, et al. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2004; 24: 658-63.
36. Chawla A, Barak Y, Nagy L, et al. PPAR gamma dependent and independent effects on macrophage-gene expresion in lipid metabolism and inflammation. Nat Med. 2001; 7: 48-53.
37. Ghanim H, Garg R, Aljada A, et al. Supression of nuclear factor kB and stimulation of inhibitor kB by troglitazone: evidence for an antiinflammatory effect and potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab. 2001; 86: 1306-12.
38. Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferators activated-receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 1999; 19: 2094-104.
39. Garg R, Kumbkarni Y, Aljada A, et al. Troglitazone reduces reactive oxygen species generation by leucocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension. 2000; 36: 430-5.
40. Tao L, Liu HR, Gao E, et al. Antioxidative, antinitrative, and vasculo-protective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation. 2003; 108: 2805-11.
41. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004; 89: 3835-40.
42. Currier J. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Metabolic update: better defining lipodystrophy and treating insulin resistance. AIDS Clin Care. 2003; 15: 79-80.
43. Xiang AH, Peters RK, Kjos SL, et al. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function. J Clin Endocrinol Metab. 2004; 89: 2846-51.
44. Grimaldi PA. The roles of PPARS in adipocyte differentiation. Progr Lipid Res. 2001; 40: 269-81.
45. Smith SR, De Jonge L, Volaufova J, et al. Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial. Metabolism. 2005; 54: 24-32.
46. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med. 2003; 115 (Suppl)8A: 42S-48S.
47. Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferators-activated receptor gamma deficiency and PPAR gamma agonist improve insulin resistance. J Biol Chem. 2001; 276: 41245-54.
48. Tontonoz P, Nagy L. Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: implications for cardiovascular disease. Curr Opin Lipidol. 1999; 10 (6): 485-90.
49. Chinetti G, Lestavel S, Fruchart JC, Clavey V, Staels B. Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ Res. 2003; 92: 212-7.
50. Thomas JC, Taylor KB. Effects of thiazolidinediones on lipoprotein subclasses in patients who are insulin resistant. Diabetes. 2001; 50 (Suppl 2): A455.
51. Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther. 2004; 26: 744-54.
52. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002; 25: 708-11.